NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
ImmunoGenesis
Genentech, Inc.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
BeOne Medicines
Servier
Children's National Research Institute
M.D. Anderson Cancer Center
Chugai Pharmaceutical
Georgetown University
Eisai Inc.
Zhejiang University
Axcynsis Therapeutics Pte Ltd
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Gilead Sciences